Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea

Inclusion Criteria:

• Patients with culture-positive stool sample with Campylobacter concisus

• Diarrheic patients ≥ 18 years

• symptoms of diarrhea defined as three or more watery stools per day or

• two watery stools per day + at least one of the following symptoms: abdominal pain,nausea, vomiting or fever.

• Diarrheic symptoms for a minimum of 24 hours before enrollment.

• Diarrheic symptoms for a maximum of 21 days before enrollment.

• Informed oral and signed written consent, with documentation that all relevantinformation about the study is given to the patient.

• The patient must be willing and able to participate in the trial.

Exclusion Criteria:

• Hypersensitivity to azithromycin, erythromycin, macrolide or otherketolide-antibiotics

• Pregnancy or breastfeeding (if relevant).

• Culture positive stool sample with a Co-pathogen.

• Treatment with other antibiotics (in any stage 21 days before the first stool sample).

• Patients with severe liver disease.

• Patients with severe renal impairment (GFR <10 ml / min).

• Patients with congenital or documented acquired QT prolongation.

• Patients treated with other active drugs that prolong the QT interval such as:antiarrhythmics of classes IA and III, cisapride and terfenadine.

• Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia.

• Patients with clinically relevant bradycardia, arrhythmia or severe heart failure.

• Inflammatory bowel diseases

• Chronic diarrhea of known cause.

• Dementia.

• Serious illness less than 21 days from the planned entry into the study.

• Patients treated with medications that have interactions with azithromycin e.g.alkaloids, ciclosporin or amiodarone.

• Patients involved in the planning or execution of the study.